Genomics

Delve Bio Appoints Jim Stuart as Chief Commercial Officer

Retrieved on: 
Monday, August 28, 2023
Science, Other Science, Research, General Health, Health, Infectious Diseases, Genetics, Clinical Trials, Quest Diagnostics, University, Bio, Genomics, University of California, San Francisco, Infection, Jim Stuart, Personalized medicine, Genentech, Fungus, Cerebrospinal fluid, Dicarboxylic acid, Parasitism, Metagenomics, Delve, Bacteria, Anne, Encephalitis, Virus, Meningitis, Management, Pharmaceutical industry

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

Key Points: 
  • Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.
  • “We’re delighted to welcome Jim to our growing team,” said Brad Murray, co-founder and CEO of Delve Bio.
  • “His track record of driving commercial success in molecular diagnostics gives us full confidence in his ability to increase physician and patient access to our mNGS test.”
    Mr. Stuart joins Delve from Invitae, where he held positions of increasing responsibility, starting as the first employee on the commercial team and culminating as senior vice president, commercial.
  • Delve Bio emerged from stealth with $35 million in Series A financing in June.

New research from The Jackson Laboratory: Insights from fully sequencing 43 human Y chromosomes

Retrieved on: 
Friday, August 25, 2023
Male, DNA, Human, National Human Genome Research Institute, Neoplasm, Y, U24, Genomics, RNA, Disorder, Clemson University, Illar Hallaste, Jackson Laboratory, Chromosome, FACMG, Heinrich Heine University Düsseldorf, Fertility, Euchromatin, JAX, Biology, Paper, Research, Health, Gene, Reference genome, Genome, Disease, Birth control, Antibiotics, Agriculture

Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.

Key Points: 
  • Even as the field of human genomics forged ahead at an astonishing pace, the Y chromosome— one of the sex chromosomes—has long remained overlooked.
  • Taken together, these two papers provide intriguing insights into human Y chromosomes, reveal the highly variable nature of Y chromosomes across individuals, and provide an important foundation for future studies on how they may be contributing to certain disorders and diseases.
  • "Our study enables the inclusion of the full Y chromosome in all future studies when sequencing male genomes to understand health and disease."
  • The work was supported in part by a U24 grant from the National Human Genome Research Institute (#HG007497).

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, August 25, 2023
Oncology, Health, Medical Devices, Hospitals, General Health, Pharmaceutical, Biotechnology, PSNL, Cancer, Employment, RSU, Genomics, Compensated emancipation, Pharmaceutical industry, Chief Justice of Hungary

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Personalis is making this announcement as required by Nasdaq rules.
  • All of the inducement stock options were granted on August 15, 2023 and have an exercise price of $1.81 per share, which is equal to the closing price of Personalis’ common stock on the grant date.
  • The foregoing inducement awards are subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering each grant.

Trace Genomics and Taurus Agricultural Marketing partner to bring next-generation soil testing to Canada

Retrieved on: 
Thursday, August 24, 2023
Metagenomics, DNA, Partnership, Canadian Agricultural Safety Association, Genomics, Fertilizer, Agriculture, AB, Consultant, Translation, Chemistry, Soil, Fertility, Nitrogen, Phosphorus, Trace, AMES

AMES, Iowa and CALGARY, AB, Aug. 24, 2023 /PRNewswire/ -- Trace Genomics (Trace), an industry-leading provider of science-validated soil biology insights, and Taurus Agricultural Marketing (Taurus Ag), market-leading distributor of agricultural products in Canada, announced an international partnership today.

Key Points: 
  • AMES, Iowa and CALGARY, AB, Aug. 24, 2023 /PRNewswire/ -- Trace Genomics (Trace), an industry-leading provider of science-validated soil biology insights, and Taurus Agricultural Marketing (Taurus Ag), market-leading distributor of agricultural products in Canada, announced an international partnership today.
  • Trace is revolutionizing agricultural soil testing by providing comprehensive, actionable insights to growers and retailers in the United States, and now, Canada.
  • "Disruptions are rare and take time, but with Trace Genomics' metagenomic approach, we're seeing a transformative shift in agricultural analytics," said Craig Davidson, President, Taurus Agricultural Marketing.
  • "Taurus Ag is a valuable partner for our expansion into Canada," said Justin Miller, Director of Sales at Trace Genomics.

Element Biosciences Adds Genomics Executive to Leadership Team to Accelerate Corporate Development

Retrieved on: 
Thursday, August 24, 2023
University of California, San Diego, Business development, University, Senior, Doctor of Philosophy, Berkeley, Yaron, Business, Genomics, Lev Hakak, Molecular biology, SAN, Corporation, Element, Biophysics, Growth, Entrepreneurship, Affymetrix, Management

SAN DIEGO, Aug. 24, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the appointment of veteran life science executive Yaron Hakak as Senior Vice President of Corporate and Business Development.

Key Points: 
  • As Element grows its commercial organization, Yaron will lead business and corporate development to accelerate the company's global growth through high impact business and strategic partnerships, joint ventures, and acquisitions.
  • "I'm thrilled to welcome Yaron to Element as we continue to expand around the world with tools to advance scientific discoveries," said Molly He, Ph.D., CEO and Co-Founder of Element Biosciences.
  • Before that, he served as Director of Business Development at Affymetrix, where he supported corporate activities related to its genomics and proteomic product portfolios.
  • "I am honored to join the Element team to help further the development and worldwide adoption of the AVITI sequencing platform," said Yaron Hakak.

Spatial Genomics & Transcriptomics Industry Forecast to 2030: Personalized Medicine Drive Fuels Demand for Spatial Genomics & Transcriptomics, Revolutionizing Precision Healthcare

Retrieved on: 
Wednesday, August 23, 2023
Tissue, Genomics, Prognosis, Research, Gene expression, USD, Data analysis, Investment, Diagnosis, Growth, Illumina, Inc., Medical imaging

DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Spatial Genomics & Transcriptomics Industry Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Spatial Genomics & Transcriptomics Industry Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The transition towards personalized medicine, which aims to provide tailored healthcare based on individual characteristics, is a pivotal factor propelling the demand for spatial genomics and transcriptomics.
  • Prominent players in the spatial genomics & transcriptomics market include Natera Inc., 10x Genomics, Dovetail Genomics, Illumina, Inc., and S2 Genomics, Inc.
  • The spatial genomics & transcriptomics market is on a trajectory of remarkable growth, driven by advancements in technology, the shift towards personalized medicine, and increasing demand for precise diagnosis and treatment strategies.

Complete Genomics Garners the Prestigious 2023 R&D 100 Awards for Cutting-Edge Innovation

Retrieved on: 
Wednesday, August 23, 2023
DTC, DNA, Completeness, Genomics, NGS, Complete Genomics, Innovation, Research, IP, Government, Science, Whole genome sequencing, Silicon, T20, SAN, Entrepreneurship, R, Health, Genome, Antibiotics

This distinguished accolade stands as a testament to Complete Genomics innovative sequencing technologies and enduring impact on the industry.

Key Points: 
  • This distinguished accolade stands as a testament to Complete Genomics innovative sequencing technologies and enduring impact on the industry.
  • With this innovation, Complete Genomics further enhances sequencing capabilities and enables researchers to accelerates scientific breakthroughs by doubling the efficiency of DNA sequencing.
  • Founded in 2005 in Silicon Valley, Complete Genomics offers complete end-to-end NGS solutions, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics.
  • Complete Genomics will formally accept the award at a gala banquet on Nov. 16, 2023 in San Diego.

FYR DIAGNOSTICS WELCOMES DR. NIALL LENNON AND DR. RYAN WALTERS TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Wednesday, August 23, 2023
SAB, Broad Institute, EV, Genomics, NGS, FYR, Liquid biopsy, Cancer, United States Air Force Scientific Advisory Board, Research, MIT, Harvard University, Associate, Cancer Diagnostic Probe, EVS, Seminal vesicles, CRSP, Management, Knowledge, Diagnosis, Translational Genomics Research Institute, Massive parallel sequencing, Broad, Medical device

MISSOULA, Mont., Aug. 23, 2023 /PRNewswire/ -- FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).

Key Points: 
  • MISSOULA, Mont., Aug. 23, 2023 /PRNewswire/ -- FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).
  • Renowned for his pivotal contributions in the fields of genomics and diagnostics, Dr. Lennon will offer valuable insights into FYR Dx's innovative use of Extracellular Vesicles (EVs) in clinical diagnostics.
  • Dr. Lennon is currently the Senior Director of Translational Genomics at the Broad Institute of MIT and Harvard.
  • Speaking to the newest additions to the team, Dr. Chris Booth, CEO of FYR Diagnostics, stated, "We are excited to welcome Dr. Lennon and Dr. Walters to our SAB.

Codetta Bio Appoints New Vice President of Product Management to Lead Commercial Strategy

Retrieved on: 
Tuesday, August 22, 2023
Data Management, Technology, Professional Services, Health, General Health, Health Technology, Other Science, Other Technology, Research, Data Analytics, Science, Drug discovery, Product management, Caliper Life Sciences, PerkinElmer, Multimedia, Patient, Genomics, Coda (music), Marketing, Bio, Software, Management

Codetta Bio , the life sciences company developing advanced multiomic biomarker measurement tools, announced today that Jeremy Lambert has joined the company as Vice President of Product Management.

Key Points: 
  • Codetta Bio , the life sciences company developing advanced multiomic biomarker measurement tools, announced today that Jeremy Lambert has joined the company as Vice President of Product Management.
  • In this role, Lambert will lead the development and execution of Codetta’s commercial strategy as the company brings its breakthrough multiomic solution to market.
  • View the full release here: https://www.businesswire.com/news/home/20230822205083/en/
    Jeremy Lambert, Vice President of Product Management at Codetta Bio (Graphic: Business Wire)
    “Jeremy has a proven track record as a strategic, customer and market-focused leader in life sciences technology product development,” said Anthony Lemmo, CEO of Codetta Bio.
  • “I’m looking forward to working alongside the rest of the Codetta team to develop a commercial strategy that will make our innovative solution widely accessible and ultimately improve outcomes for patients everywhere.”
    To learn more about Codetta Bio, please visit http://www.codettabio.com .

NEW STUDY SHOWS UROAMP CAN DETECT BLADDER CANCER NOT FOUND BY CYSTOSCOPY OR URINE CYTOLOGY

Retrieved on: 
Tuesday, August 22, 2023
Carcinoma, DNA, Urine, Genomics, Cancer, AUA, Pathology, Clinical Cancer Research, American Urological Association, Bladder cancer, Harvard Medical School, American Cancer Society, Doctor of Philosophy, Assistant, Genome, MD, Patient, Risk, SAN, Blood, Annual general meeting, Cystoscopy, Diagnosis, Research, Massachusetts General Hospital, FDA, Recurrence, Hematuria, Disease, Dietary supplement, Nursing, Antibiotics, Medical imaging, Urology

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2023 /PRNewswire/ -- UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research.

Key Points: 
  • In a multi-center case-control study, researchers from leading academic centers and urology practices throughout the United States* compared UroAmp's diagnostic and prognostic performance for bladder cancer to standard-of-care procedures, like cystoscopy, cytology and pathology.
  • UroAmp uses next-generation DNA sequencing to deeply interrogate 60 of the most high-impact urothelial cancer genes for mutations while broadly measuring changes across the whole genome.
  • A comprehensive genomic profile is then generated providing prognostic information about a patient's cancer and predicted responses to genome-targeted drug therapies.
  • The study builds upon recent discoveries from large public research efforts , further defining the most important areas of the genome commonly mutated in bladder cancer.